– USA, CA – ChemoCentryx, Inc. (Nasdaq: CCXI), today announced the appointment of Jennifer Herron to its Board as an Independent Director, effective June 28, 2022, bringing the Board to nine members.
“With more than 25 years developing and refining her therapeutics commercial expertise, Jennifer is uniquely positioned to add immediate value to our TAVNEOS commercial efforts,” said CEO, Dr. Tom Schal. “Jennifer’s values closely align with our organization, and we are confident this addition benefits patients, caregivers, and shareholders alike as we continue to grow and bring TAVNEOS to appropriate patients in need.”
About Jennifer L. Herron
Jennifer Herron serves as SVP and CCCO of ADC Therapeutics, which she joined in November 2019 to build its commercial organization and launch its first marketed product. Before ADC Therapeutics, she was EVP and CCCO at Immunogen and President and EVP, Global Commercial, at MorphoSys US. In 2016 and 2017, Ms. Herron led the Commercial organization at Ariad Pharmaceuticals as EVP and CCO and prepared the organization to launch its second commercial product. Earlier in her career, she held commercial leadership roles of increasing responsibility with Bristol-Myers Squibb, Novartis Oncology, and SmithKline Beecham Oncology (GlaxoSmithKline).
“TAVNEOS is truly a unique medicine with the potential to improve the lives of many patients that have been underserved for far too long,” said Jennifer Herron. “I look forward to bringing my experience to ChemoCentryx, supplementing an already strong team with growing expertise in drug discovery, development, and commercial execution.”
Ms. Herron holds an MBA from Georgetown University and a BA in Biology and Economics from Lehigh University.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe hidradenitis suppurativa and C3 glomerulopathy.
ChemoCentryx is also developing CCX559, a highly potent orally administered small molecule PD-L1 checkpoint inhibitor, for the treatment of patients with solid tumors. A Phase I dose-escalation study for CCX559 is ongoing and ChemoCentryx plans to advance to a Phase Ib/II study in the second half of 2022.
Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and cancer.
For more information: https://www.chemocentryx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
